Policy & Regulation
Iqvia, NRx Pharmaceuticals Collaborate on Potential Medical Support for Novel COVID-19 Treatment
14 September 2021 - - US-based life sciences industry analytics, technology solutions and clinical research services supplier Iqvia (NYSE: IQV) has forged a collaboration with NRx Pharmaceuticals (NASDAQ: NRXP), the company said.

NRx is a company dedicated to creating innovative, life-saving treatments and bringing hope to those facing life-altering conditions with no approved disease-modifying therapies or cures.

Iqvia will collaborate with NRx as its designated partner, to provide pharmacovigilance services and medical information in preparation for potential regulatory actions.

This collaboration will allow NRx to access Iqvia's domain experience with COVID-19, our unparalleled data assets, and analytics to support potential emergency use authorization of Zyesami.

Iqvia will work closely with NRx to support key activities required for EUA activation, including the pharmacovigilance and medical information programs.

NRx Pharmaceuticals (NASDAQ-GS: NRXP) draws upon more than 300 combined years of scientific and drug-development experience to bring improved health to patients.

Its investigational product, Zyesami (aviptadil) for patients with COVID-19, has been granted Fast Track designation by the US Food and Drug Administration and is currently undergoing phase 3 trials funded by the US National Institutes of Health, the Biomedical Advanced Research and Development Authority part of the US Department of Health and Human Services, and the Medical Countermeasures program, part of the US Department of Defense.

Iqvia (NYSE: IQV) is a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry.

With approximately 74,000 employees, Iqvia conducts operations in more than 100 countries.


Related Headlines